GSK plugs into bioelectronics with $50 million venture fund

LONDON (Reuters) – GlaxoSmithKline raised its bet on using electrical signals in the body to target diseases on Thursday with the launch of a $50 million strategic venture capital fund. Britain's biggest drugmaker hopes to have the first medicine that effectively speaks the electrical "language" of the body ready for approval by the end of this decade. GSK said the new fund's first investment would be in SetPoint Medical, a California company working on implantable devices to treat inflammatory diseases. …